This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
Companion FOAs:
PAR-21-122 , R61/ R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
PAR-21-124 , R61/ R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
Deadlines:
- Application Due Dates: June 17, 2021; Oct 19, 2021; Feb 22, 2022; June 21, 2022; Oct 18, 2022; Feb 21, 2023; June 20, 2023; Oct 20, 2023; Feb 20, 2024; June 20, 2024; Oct. 21, 2024
PAR-21-123 Expiration Date New Date October 22, 2024 per issuance of NOT-NS-24-048. (Original Expiration Date: July 13, 2024)
Direct Costs cannot exceed $499,000 in any one year and cumulative direct costs for the 3 year project cannot exceed $750,000.